Rapalogs, as inhibitors of mTOR, have demonstrated clinical value, not only in the regulation of abnormal immune responses found in benign hematologic diseases, but also for the treatment of hematological malignancies (Table 2). The gene discussed is MTOR; the disease is hematologic disorder.